EXEL - EXELIXIS, INC.

QQQ $ 612.14 $ 1.56 (0.26 %)

DIA $ 470.45 $ 1.64 (0.35 %)

SPY $ 672.31 $ 2.95 (0.44 %)

TLT $ 89.45 $ -0.19 (-0.21 %)

GLD $ 367.77 $ 0.35 (0.1 %)

Previous Close

$ 40.81

Open

$ 40.63

Bid

$ 39.15 x 30

Ask

$ 41.50 x 60

Day's Range

$ 39.93 - $ 40.83

52 Week Range

$ 31.90 - $ 49.62

Volume

2,321,902

Average Volume

Market Cap

10.94B

Beta (5Y Monthly)

$ 0.68

PE Ratio (TTM)

$ 16.14

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	11-04-2025	10-03-2025	10-Q
2	07-28-2025	07-04-2025	10-Q
3	05-13-2025	04-04-2025	10-Q
4	02-11-2025	01-03-2025	10-K
5	10-29-2024	09-27-2024	10-Q
6	08-06-2024	06-28-2024	10-Q
7	04-30-2024	03-29-2024	10-Q
8	02-06-2024	12-29-2023	10-K
9	11-01-2023	09-29-2023	10-Q
10	08-01-2023	06-30-2023	10-Q
11	05-09-2023	03-31-2023	10-Q
12	02-07-2023	12-30-2022	10-K
13	11-01-2022	09-30-2022	10-Q
14	08-09-2022	07-01-2022	10-Q
15	05-10-2022	04-01-2022	10-Q
16	02-18-2022	12-31-2021	10-K
17	11-02-2021	10-01-2021	10-Q
18	08-05-2021	07-02-2021	10-Q
19	05-06-2021	04-02-2021	10-Q
20	02-11-2021	01-01-2021	10-K
21	11-05-2020	10-02-2020	10-Q
22	08-06-2020	07-03-2020	10-Q
23	05-05-2020	04-03-2020	10-Q
24	02-25-2020	01-03-2020	10-K
25	10-30-2019	09-27-2019	10-Q
26	07-31-2019	06-28-2019	10-Q
27	05-01-2019	03-29-2019	10-Q
28	02-22-2019	12-28-2018	10-K
29	11-01-2018	09-28-2018	10-Q
30	08-01-2018	06-29-2018	10-Q
31	05-02-2018	03-30-2018	10-Q
32	02-26-2018	12-29-2017	10-K
33	11-01-2017	09-29-2017	10-Q
34	08-02-2017	06-30-2017	10-Q
35	05-01-2017	03-31-2017	10-Q
36	02-27-2017	12-30-2016	10-K
37	11-03-2016	09-30-2016	10-Q
38	08-03-2016	07-01-2016	10-Q
39	05-04-2016	04-01-2016	10-Q
40	02-29-2016	01-01-2016	10-K

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

UBS Maintains Neutral on Exelixis, Raises ...
11/06/2025 17:36:29

UBS analyst Ashwani Verma maintains Exelixis (NASDAQ:EXEL) with a Neutral and raises the price target from $35 to $40.

TD Cowen Maintains Buy on Exelixis, Raises...
11/05/2025 18:48:22

TD Cowen analyst Yaron Werber maintains Exelixis (NASDAQ:EXEL) with a Buy and raises the price target from $44 to $51.

Morgan Stanley Maintains Overweight on Exe...
11/05/2025 18:05:48

Morgan Stanley analyst Sean Laaman maintains Exelixis (NASDAQ:EXEL) with a Overweight and raises the price target from $44 t...

Barclays Maintains Equal-Weight on Exelixi...
11/05/2025 17:21:26

Barclays analyst Etzer Darout maintains Exelixis (NASDAQ:EXEL) with a Equal-Weight and raises the price target from $40 to $41.

HC Wainwright & Co. Maintains Buy on Exeli...
11/05/2025 16:34:16

HC Wainwright & Co. analyst Robert Burns maintains Exelixis (NASDAQ:EXEL) with a Buy and raises the price target from $4...

Exelixis Authorizes $750M Stock Repurchase...
11/04/2025 22:36:57

- SEC Filing

Exelixis Raises FY2025 Sales Guidance from...
11/04/2025 21:11:23

Exelixis (NASDAQ:EXEL) raises FY2025 sales outlook from $2.250 billion-$2.350 billion to $2.300 billion-$2.350 billion vs $2.32...

Exelixis Q3 Adj. EPS $0.78 Beats $0.61 Est...
11/04/2025 21:06:14

Exelixis (NASDAQ:EXEL) reported quarterly earnings of $0.78 per share which beat the analyst consensus estimate of $0.61 by 27....

Earnings Scheduled For November 4, 2025
11/04/2025 11:12:08

Guggenheim Downgrades Exelixis to Neutral
11/03/2025 17:07:53

Guggenheim analyst Michael W. Schmidt downgrades Exelixis (NASDAQ:EXEL) from Buy to Neutral.

Preview: Exelixis's Earnings
11/03/2025 15:03:11

What's Driving the Market Sentiment Around...
10/30/2025 17:00:38

mercks-new-cancer-therapy-combo-shows-significant-edge-over-rivals-in-renal-cancer

Merck's New Cancer Therapy Combo Shows Sig...
10/28/2025 17:40:16

Merck and Eisai report Phase 3 results showing Welireg plus Lenvima significantly improved progression-free survival in advance...

Morgan Stanley Maintains Overweight on Exe...
10/21/2025 17:11:01

Morgan Stanley analyst Sean Laaman maintains Exelixis (NASDAQ:EXEL) with a Overweight and lowers the price target from $50 t...

RBC Capital Reiterates Sector Perform on E...
10/21/2025 14:37:17

RBC Capital analyst Leonid Timashev reiterates Exelixis (NASDAQ:EXEL) with a Sector Perform and maintains $45 price target.

Wells Fargo Maintains Equal-Weight on Exel...
10/21/2025 13:07:35

Wells Fargo analyst Derek Archila maintains Exelixis (NASDAQ:EXEL) with a Equal-Weight and lowers the price target from $36 ...

this-nextracker-analyst-turns-bullish-here-are-top-5-upgrades-for-tuesday

This Nextracker Analyst Turns Bullish; Her...
10/21/2025 12:27:16

Leerink Partners Upgrades Exelixis to Outp...
10/21/2025 10:27:38

Leerink Partners analyst Christopher Liu upgrades Exelixis (NASDAQ:EXEL) from Market Perform to Outperform and announces $48...

exelixis-stock-falls-after-phase-3-colorectal-cancer-trial-shows-mixed-results

Exelixis Stock Falls After Phase 3 Colorec...
10/20/2025 14:48:53

Exelixis stock dips after Phase 3 data show modest survival gains from zanzalintinib and Tecentriq combo in colorectal cancer p...

olema-pharmaceuticals-exelixis-genmab-and-other-big-stocks-moving-lower-in-mondays-pre-market-session

Olema Pharmaceuticals, Exelixis, Genmab An...
10/20/2025 12:10:45